Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate plasma levels of hepatotoxic anti-tuberculous drugs (isoniazid, rifampicin, pyrazinamide plus significant metabolites) among patients on antituberculosis treatment (ATT) and compare the same among those who develop drug induced hepatitis on follow up versus those who do not.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity

NCT01456845

Hepatitis Tuberculosis

COMPLETED

Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage

NCT00405301

Drug Induced Hepatotoxicity Tuberculosis

COMPLETED PHASE4

Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment

NCT01395654

Hepatitis Tuberculosis, Pulmonary

UNKNOWN PHASE4

Brief Bactericidal Activity of Anti-Tuberculosis Drugs

NCT02236078

Tuberculosis Drug-resistant Tuberculosis Isoniazid Resistant Tuberculosis (Disorder)

COMPLETED PHASE1

Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease

NCT01677871

Chronic Liver Disease With Tuberclosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis (TB) is a major health problem in both the developing and developed countries because of its resurgence in the immunosuppressed patients. World Health Organization (WHO) in 1993 declared tuberculosis to be a 'global emergency' with more than a third of the world's population infected. Globally 8.9 million new cases of tuberculosis occur annually, of which 1.8 million (20%) occur in India.

Short-course chemotherapy containing isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) has proved to be highly effective in the treatment of tuberculosis. One of its adverse effects is hepatotoxicity. It is the most common side effect leading to interruption of therapy. It is associated with mortality of 6-12% if these drugs are continued even after the onset of symptoms. Risk of hepatotoxicity is increased when these drugs are combined.

The time interval between the start of anti-TB drugs and appearance of hepatotoxicity varies from 3 to 135 days. In most cases hepatitis is evident within three months of start of antituberculosis treatment (ATT).

The pathogenesis of drug-induced hepatotoxicity (DIH) is still not entirely clear for most anti TB drugs including rifampicin. Hypersensitivity is a definite possibility Rifampicin induced hepatitis has been postulated to occur as a part of systemic allergic reaction and, due to unconjugated hyperbilirubinaemia as a result of competition with bilirubin for uptake at hepatocyte plasma membrane. DIH caused by rifampicin occurs earlier as compared to isoniazid. While a dose related toxicity may exist, a direct correlation between serum drug levels and hepatotoxicity has not been well reported. Thus the clinical relevance of therapeutic monitoring of serum rifampicin concentrations in managing DIH is still being explored.

Present study done to observe serum rifampicin, isoniazid, pyrazinamide level in patients on ATT and to compare it retrospectively between patients who develop drug induced hepatitis vs those who do not.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.

Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed to be suffering from CatI/CatIII tuberculosis by a physician
2. Age: 16-65 years
3. Patient having normal baseline Liver function (AST/ALT1 \< 50/50, serum bilirubin \< 1.5 mg/dl)

Exclusion Criteria

1. Patients receiving any other drug known to be metabolized by liver by cytochrome P450 3A4 or P-glycoprotein
2. Patients diagnosed to have acute viral hepatitis A, B, C, or E or carrier for HBV \& HCV
3. Known HIV positive patients
4. Presence of chronic liver disease or renal insufficiency
5. Concomitant administration of other potential hepatotoxic drugs (methotrexate, phenytoin, valproate)
6. Chronic alcoholics who consume \> 48 g of alcohol/day for at least one year
7. Pregnant women
8. Subjects not willing to participate
9. Known patients with malabsorption or drug abuse

Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No